Assembly Biosciences, Inc.

NASDAQ:ASMB

Biotechnology

Healthcare
$22.39 +0.66%

+$0.16 today

Market cap
$458.48M
Beta
1.08
P/E (TTM)
-64.4
EPS (TTM)
-$0.38
52W Low $16.50High $39.71

Volume 0.49M

Average 0.17M

ASMB Gross Margin

Gross profit as a percentage of revenue, showing how much of each sales dollar is kept after direct costs.

Assembly Biosciences, Inc.NASDAQ: ASMB

Gross Margin · Q1 FY2026 · quarter ended Mar 2026

Gross margin widens to 99.7%

Gross margin was 99.7% in Q1 FY2026, up 157.4 pp from a year earlier. On a trailing-twelve-month basis it was 77.2%, up 110.0 pp year over year.

Context

  • Gross margin widened in 2 of the last 2 fiscal years.
  • FY2025 was the highest level in the 3 fiscal years shown.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
99.7%-0.2 pp QoQ
Last fiscal yearDec 2025
99.8%+195.9 pp YoY
LTMMar 2026
77.2%+110.0 pp YoY
Gross Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter+157.4 pp——
1 year+195.9 pp——
3 years———
5 years——
10 years——

Gross Margin history

Percent of revenue · from the income statement

Latest · FY2025
99.8%
Year-over-year change
+195.9pp

Gross Margin vs competitors

How ASMB compares with its peers on the latest reported figures

  • ASMB's LTM Mar 2026 gross margin of 77.2% is the lowest of the 4 companies compared; the peer median is 100.0%.
  • Its year-over-year change of +110.0 pp is the 3rd highest of 4, against a peer median of +277.5 pp.
ASMB Competitors Peer median
Gross Margin for ASMB and competitors
Company Period LTM level YoY 3-year change
VIRVir Biotechnology, Inc.LTM Mar 2026275.2% +2604.6 pp+21.4 pp
ABUSArbutus Biopharma CorporationLTM Mar 2026100.0% +277.5 pp-2.6 pp
ENTAEnanta Pharmaceuticals, Inc.LTM Mar 202698.3% -1.7 pp-7.0 pp
ASMBAssembly Biosciences, Inc.LTM Mar 202677.2% +110.0 pp—
INDPIndaptus Therapeutics, Inc.FY2025— ——
AVIRAtea Pharmaceuticals, Inc.FY2025— ——
Peer median (excluding ASMB) 100.0%+277.5 pp-2.6 pp

Competitors are the stored peer set for ASMB. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue6.25M07.16M28.52M72.3M
Cost of Revenue069.08M48.9M55.93M129K
Gross Profit6.25M(69.08M)(41.74M)(27.41M)72.17M
Gross Margin100.0%—-582.7%-96.1%99.8%
Research & Development68.52M69.98M48.9M55.93M64.81M
Selling, General & Admin28.78M23.93M22.91M18.01M19.61M
Operating Expenses138.94M25.03M22.91M18.01M84.42M
Depreciation & Amortization466K498K450K129K129K
EBITDA(90.58M)(92.52M)(60.75M)(39.72M)(5.99M)
EBITDA Margin-1448.4%—-848.0%-139.3%-8.3%
Operating Income(132.69M)(94.11M)(64.65M)(45.42M)(12.12M)
Operating Margin-2121.7%—-902.5%-159.3%-16.8%
Interest Income302K1.02M3.45M5.57M6M
Interest Expense00000
Other Income / Expenses302K1.02M3.45M5.57M6M
Income Before Tax(132.39M)(93.09M)(61.2M)(39.85M)(6.12M)
Pre-Tax Margin-2116.8%—-854.3%-139.7%-8.5%
Income Tax Expense(2.53M)033K330K0
Net Income(129.86M)(93.09M)(61.23M)(40.18M)(6.12M)
Net Margin-2076.4%—-854.8%-140.9%-8.5%
EPS (Basic)(36.00)(22.82)(13.38)(6.69)(0.55)
EPS (Diluted)(36.00)(22.82)(13.38)(6.69)(0.55)
Weighted Avg Shares3.61M4.03M4.58M6M11.21M
Weighted Avg Shares (Diluted)3.61M4.03M4.58M6M11.21M

Assembly Biosciences, Inc.

NASDAQ:ASMB

Intrinsic Alpha fair value

Locked

Current Price

$22.39

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.